Merck & Co., Inc. (MRK)
Merck's therapy for rare lung condition shown to help reduce risk of death in study
Merck said on Monday its drug, Winrevair, helped significantly reduce the risk of death in patients with a rare condition which causes high blood pressure in the lungs, months after it secured approval in the United States.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Not A Banana: 2 (Special) Dividend Stocks Offering Ultra-Deep Value
In today's market, many investors are distracted by hype. But the real value lies in stocks that provide strong, consistent dividend yields without the noise. Instead of chasing the latest trends, focusing on high-yield dividend stocks that are undervalued is a smart strategy for building wealth over time. Two of my picks offer both deep value and high yields, making them standout opportunities for any dividend-focused portfolio.
Merck Stock Trades Near 52-Week Low: What's Next for Investors?
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference
Merck & Co., Inc. (NYSE:MRK ) Jefferies London Healthcare Conference November 21, 2024 6:30 AM ET Corporate Participants Joe Romanelli - President, Human Health International Marjorie Green - SVP and Head of Oncology, Global Clinical Development, Merck Research Laboratories Conference Call Participants Akash Tewari - Jefferies Akash Tewari Good morning, everyone Day 3. We're at the end of it.
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
In recent weeks, financial participants have remained pessimistic about Merck's development prospects, partly due to the nomination of Robert F. Kennedy Jr. as head of HHS. However, I believe Mr. Market overreacted to this news, given the strong performance of Merck's oncology franchise in recent quarters. So, sales of Keytruda amounted to $7.43 billion for the three months ended September 30, 2024, an increase of 17.2% year-over-year.
Merck's Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.
The company has been preparing for the 2028 expiration of its patents protecting Keytruda.
Injectable version of cancer drug Keytruda works as well as current IV form: Merck
CNBC's Angelica Peebles reports on news from Merck.
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
The news may help Merck retain sales of Keytruda, which is the world's best-selling drug.
Merck says Keytruda injection on par with approved IV version in trial
Merck said on Tuesday a study showed that its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its treatment, likely making it even more accessible and easier to administer.
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant pleural mesothelioma.
